Spero Therapeutics Inc

NASDAQ:SPROUnited States

Nov 14, 2024

Show headlines and story abstract

• -- Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $13.5M, from 4:08PM ET on Thursday Nov 14, 2024 by MT Newswires

  4:08PM ET on Thursday Nov 14, 2024 by MT Newswires
  Companies Mentioned: SPRO
  04:08 PM EST, 11/14/2024 (MT Newswires) -- ...

• Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: SPRO
  
  additional funding; the ability to commercialize Spero's product candidates, if approved; Spero's ability to retain key personnel; Spero's leadership transitions; whether Spero's cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the "Risk Factors" set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Spero explicitly disclaims any obligation to update any forward-looking statements.
  

• *DJ Spero Therapeutics 3Q Loss/Shr 32c >SPRO, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones

  4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
  Companies Mentioned: SPRO
  
  additional funding; the ability to commercialize Spero's product candidates, if approved; Spero's ability to retain key personnel; Spero's leadership transitions; whether Spero's cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the "Risk Factors" set forth in filings that Spero periodically makes with the SEC. The forward-looking statements included in this press release represent Spero's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Except as required by law, Spero explicitly disclaims any obligation to update any forward-looking statements.